Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT04772989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04772989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2021
Completion date
August 25, 2025
Enrollment
94 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervical cancer, diffuse large b cell lymphoma (dlbcl), esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, lymphoma, non-hodgkin, melanoma, multiple myeloma, non small cell lung cancer (nsclc)